Company: KROS
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001664710-25-000018
Chunk: 34

Company: Keros Therapeutics, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 7A
Chunk 34
---
ment Agreement by and between the registrant and Christopher Rovaldi, dated as of January 28, 2022 effective as of February 1, 2022.8-K001-3926410.1January 31, 202210.20+First Amendment to the Employment Agreement by and between the registrant and Keith Regnante, dated as of January 1, 2022.10-K001-3926410.21March 9, 202210.21+First Amendment to the Employment Agreement by and between the registrant and Simon Cooper, dated as of January 1, 2022.10-K001-3926410.22March 9, 202210.22Indenture of Lease by and between the registrant and Revolution Labs Owner, LLC, dated September 7, 2021.10-Q001-3926410.1November 4, 202110.23First Amendment to Lease, by and between the registrant and Revolution Labs Owner, LLC, dated January 6, 2023.10-Q001-3926410.1May 4, 202310.24*#Exclusive License Agreement by and between the registrant and Takeda Pharmaceuticals U.S.A., Inc., dated as of December 3, 2024.

113

10.25+Employment Agreement by and between the registrant and Yung H. Chyung, dated as of October 15, 2024 effective as of November 1, 2024.8-K001-3926410.1October 16, 202419*Insider Trading Policy.21.1*Subsidiaries of Keros Therapeutics, Inc.23.1*Consent of Independent Registered Public Accounting Firm.31.1*    Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.31.2*Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.32.1**Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S